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879-5 Beta Radiation With Direct Stenting: Final Results of the 
BRIDGE Trial 
Patrick W. Serruvs, Willlam Wijns, Ivan de Scheerder, Paul A. van den Heuvel, Wolfgang 
Rutsch. Helmut D. Gloaar. Carlos Macava. Pierre H. Materne. Heike Vonhausen. Patricia 
I  
C. Otto-Terlouw, Erasmus Medical Center, Rotterdam, The Netherlands 
The BRIDGE study is a mulhcenter, randomized controlled clinical trial evaluating the 
acute and long-term efficacy of intravascular brachyiherapy (VET) with P-32 immediately 
following direct stenting (20 Gy 1 mm inside the coronary wall). 
VBT at the time of stem implantation for de nw0 lesions has not yielded good results and 
IS presently abandoned. We wanted to revisit this approach and have tried to optimize all 
procedural steps: ideal case selection, use of Ilb-llla blockers, direct stenting. awdance 
of edge damage, source centering, IVUS guided dosimetry and adequate radiation cov- 
erage. Patients were randomized to VBT or no-VBT. The sample size has at least 64% 
power to detect a 50% decrease I” loss of MLD as assessed by QCA at 6 months (pri- 
mary endpoint). The secondary endpornts are clinical and safety outcomes (I, 6 and 12 
mths), restenosis (50% diameter stenosis), remodelling and neo-intimal hyperplasia by 
IVUS, late thrombotic occlusion (up to 12 mths). Inclusion criteria: stable or unstable 
angina or documented silent ischemia with one or two successfully stented de nwo 
lesions at least 2.5-4.0 mm in diameter and up to ISmm long. Between Feb 2001 and 
Mar 2002, 112 patients (1.04 lesionslpt) were randomized to VBT or no-VBT at 8 sites in 
Europe. Of the VBT patients 93% were successfully treated. Baseline characteristics: 
age 60.5 yrs. male 79.8%, unstable 25.5%, stable angina 68.2%, silent ischemia 5.5%. 
Pre-procedure (N=81): mean vessel size was 2.84 vs. 2.65 mm, MLD was 0.95 vs. 1.05 
mm and lesson length was 10.9 vs. 11 .O mm (VBT vs. no-VBT). Post-procedure: mean 
vessel size was 2.63 vs. 2.82 mm and MLD was 1.78 vs. 2.04 mm. Stented segment: 
mean vessel size was 3.04 vs. 3.03 mm, MLD post was 2.69 vs. 2.67 mm, diameter 
stenosis was 11 vs. 12 % (VBT vs. no-VBT). Irradiated segment (defined by the length of 
the effective radiabon source, full dose prescribed): mean vessel size was 2.98 mm, MLD 
post was 2.05 mm, diameter stenosis was 32%. MACCE up to 30 days: death O%, Q-MI 
1.8%. non-Q-MI 2.7%, CABG 0%. re-PTCA 0.9% and 1.8% sub-acute occlusion. 
The final results, including 12 months follow-up, will be presented during the meeting. 
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879-6 Sirolimus-Eluting Stent or lntracoronary Brachytherapy 
to Treat In-Stent Restenosis 
Fausto Feres. Juan S. Munoz, Alexandre A. Abizaid, Rodolfo Staico, Luiz A. Mattes, 
Gala Maldonado, Marinella Centernero. Luiz F. Tanajura, Aurea J. Chaves, lbraim Pinto, 
Andrea S. Abizaid, Amanda Sousa, Jose Eduardo M. Sousa, Institute Dante Pazzanese 
of Cardiology, Sao Paula, Brazil 
Background: lntracoronary Beta-Radiation Therapy (BT) has been shown to be effec- 
tive to treat in-stent restenosis (ISR) in large randomized clinical trials. Drug- eluting 
stems (DES) also have been successfully used to treat ISR in small pilot studies. The 
purpose of this study is to report clinical and angiographic outcomes of patients (Pts) with 
ISR treated either with balloon angioplasty followed by BT or DES. 
Methods: From March 2001 to April 2002, 50 consecutive pts with ISR were treated 
either with Sirolimus- eluting stent or BT (Novoste,Beta-Cath).The first 25 pts were 
treated with DES (one or two 18 mm Cypher stent were used per patient) and the second 
25 treated with BT (40 mm source). Angiographic quantifications were performed in all 
pts at baseline (Post) and the follow-up (FUP) (12 months for DES and 6 months for BT). 
Results: Clinical FUP was available at 12 months for all pts in DES group and for 22 
(88%) in the ??T group who completed 6 months FUP. 100% of DES group and 82% of 
the BT group were free of MACE (TVR, AMI or death)-p=0.04. Angiographic FUP was 
done in all DES group at 12 months and 86% of the pts in BT group (19/22). 
Angiographic Results(mm) DES(n=25) BT(n=19) 
In-lesion length 
Reference Diameter Post 
MLD Pre 
MLD in-segment Post 
MLD in-stent Post 
%DS Pre 
%DS In-segment Post 
%DS in-stem Post 
Acute gal” 
Reference Diameter FUP 
MLD in-segment FUP 
MLD in-stent FUP 
Late loss in-segment 
Late 10s in-stent 
Angiographic restenosls 
13.66e7.80 16.74e3.63 
2.8*0.36 2.70+0.35 
1.05+0.31 1.08+0.34 
2.35i0.37 1.98*0.30 
2.72+0.31 1.99*0.31’ 
62.06i10.71 63.5li8.90 
16.13+8.14 28.54e7.94’ 
2.56k9.21 29.73+8.28’ 
1.67eO.34 0.91*0.43’ 
2.78+0.34 2.6220.33 
2.19*0.56 1.49*0.24 
2.36eO.57 1.90*0.31’ 
0.16iO.42 0.49*0.13 
0.35io.45 0.10*0.29 
1(4%) 3 (15.7%) 
’ p 2 0.05 vs. DES. MLD: minimal lumen diameter. %DS: % Stenosis diameter. 
Conclusions: DES group presented better acute and late results (larger MLD post, FUP 
and acute gain). Although BT group had a smaller late loss in-stent, angiographic rest- 
enosis and MACE were smaller in the DES group. because of late loss in-segment in this 
group was much smaller. 
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B8OFO-2 Bivalirudin Provides Increasing Benefit With Declining 
Renal Function in Percutaneous Coronary Intervention: 
A Meta-Analysis of 5,035 Patients Enrolled in Three 
Randomized Trials 
Derek P. Chew, Deepak L. Bhatt, Peter B. Berger, Tim Henry, Peter A. McCullough, 
Frederick Feit, John A. Binl, A. Michael Lincoff Flinders Medical Center, Adelaide, 
Australia, The Cleveland Clinic Foundation. Cleveland, OH 
Background: Chronic kidney disease is associated with an increased risk of both 
ischemic and bleeding events during PCI. Bivalirudin reduces both bleeding and 
ischemic complications. We sought to assess the magnitude of benefit in patients strati- 
fied by renal function. 
Methods: We performed a meta-analysis of three randomized trials (BAT, REPLACE-l 
and CACHET) comparing bivalirudin with heparin during PCI in which 5035 pts were 
enrolled. Stratification by renal function was performed by estimated glomerular filtration 
rate (eGFR) as determined by the Cockcroft-Gault equation: >90mls/min (n=l578; 31%]; 
90-80mldmin [n=2163; 43%], 59.30 mls/min (n=l255; 25%], <30ml/min [n=39; I%]. Trial 
specific eGFR strata for death, MI revascularization and hemorrhage were combined 
with a random-effects model. 
Results: lschemlc and bleeding event rates increased with declining eGFR. Across 
strata, the relative benefit of bivalirudin vs. heparin with respect to ischemic events [>90: 
0.79, 90-60:0.73, 59-30: 0.77, ~30: 0.811, and bleeding events [>90: 0.45, 90-60:0.40, 
59-30: 0.461 was maintained. Consequently, the benefit in terms of absolute ischemic 
and bleeding events increased with declining renal function (interactlon p=O.O44). 
Conclusion: Renal dysfunction remains a prevalent risk factor for ischemic and bleeding 
events among patients undergoing PCI. Bivalirudin provides greater absolute benefit in 
reducing these adverse events in patients with impaired renal function. 
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88OFO-3 A Prospective, Randomized Placebo-Controlled 
Multicenter Trial Evaluating Fenoldopam Mesylate for 
the Prevention of Contrast Induced Nephropathy: The 
CONTRAST Trial 
Grew W. Stone, Peter McCullough, James Tumlin. Hooman Madyoon. Patrick Murray, 
Andrew Wang, A. Alan Chu. Gary Schaer, Melissa Stevens, Robert L. Wilensky, William 
W. O’Neill, Norman Leper, Cardiovascular Research Foundation and Lenox Hill Heart 
and Vascular Institute, New York, NY 
Background. Contrast-induced nephropathy (CIN) is cmnm~n in pts with basellne 
chronic renal insufficiency undergoing invasive cardiac procedures, and is a powerful 
predictor of early and late morbidity and mortality. Fenoldopam mesylate is a selective 
dopamine-1 agonist that preserves renal medullary blood flow, and has shown promise 
in small studies in preventing CIN. 
We therefore performed a large, multicenter. prospective randomized trial to evaluate 
this agent in pts at risk for CIN. 
Methods.315 pts at 28 U.S. centers with a baseline creatinine clearance (CrCl) of ~60 
cclmin not on dialysis undergoing cardiac catheterization + angioplasty were hydrated 
and randomized 1 :I to I.V.fenoldopam (0.05 uglkglmin titrated up to 0.10 ugikglmin) vs. 
matching placebo, starting 1 hour prior to angiography and continuing for 12 hours there- 
after. Serum creatinine levels were measured at baseline, and at I, 24, 48 and between 
72-98 hours following completion of study drug, and analyzed at a central biochemistry 
lab. The primary endpoint was the incidence of CIN, defined as an increase in serum cre- 
